Angelini Ventures has co-led a €105 million Series A financing round for French biopharmaceutical company Adcytherix, focusing on innovative antibody-drug conjugates for cancer treatment.

Target Company Overview

Adcytherix is a cutting-edge biopharmaceutical company based in France, specializing in the development of innovative antibody-drug conjugates (ADCs). The company is dedicated to addressing significant unmet medical needs in cancer treatment through its pioneering research and development efforts. Adcytherix seeks to leverage advanced technologies to create therapeutic solutions that improve patient outcomes.

In 2025, Adcytherix has successfully secured €105 million in a Series A financing round, marking the largest Series A in the ADC sector in Europe. This substantial investment will enable the company to advance its lead therapeutic candidate, ADCX-020, into clinical trials, with anticipated regulatory submissions targeted for the end of 2025. Additionally, the fund will support the expansion of Adcytherix's proprietary ADC pipeline, utilizing cutting-edge payload technologies to counteract treatment resistance in various cancer types.

Industry Overview in France

The biotechnology industry in France is a robust and rapidly growing sector, characterized by significant innovation and investment. France boasts a rich ecosystem of research institutions, universities, and collaborative networks that are vital for biopharmaceutical advancements. The country's regulatory environment is supportive of clinical trials and product approvals, encouraging the growth of companies like Adcytherix dedicated to transformative cancer therapies.

In recent years, there has been an increased focus on personalized medicine and targeted therapies within the French biopharmaceutical landscape. This trend aligns well with the objectives of companies developing ADCs, as these treatments allow for tailored therapies that can address specific cancer types with high precision. With a strong government commitment to health innovation and public-private partnerships, the environment for biopharmaceutical development continues to thrive.

Furthermore, the rising prevalence of cancer globally, coupled with the pressing need for new and effective treatment options, has heightened interest and investment in the ADC space. As stakeholders across the biotech ecosystem recognize the potential of ADCs to revolutionize cancer care, opportunities for growth and collaboration in France are expected to expand significantly.

France’s strategic location in Europe also positions it favorably for international collaborations and market access, enhancing the competitive landscape for biopharmaceutical com